iguratimod has been researched along with Bone Loss, Osteoclastic in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ebina, K; Etani, Y; Goshima, A; Hirao, M; Kanamoto, T; Miura, T; Miyama, A; Nakata, K; Okamura, G; Oyama, S; Takami, K; Yoshikawa, H | 1 |
| Guo, FJ; Guo, JC; Huang, JM; Jing, XZ; Sun, Y; Wu, YX; Xiang, W; Ye, YP; Yu, SY; Zhang, P | 1 |
| Feng, X; Gan, K; Tan, W; Wang, F; Xu, L; Yang, L; Zhang, M; Zhang, Q | 1 |
| Peng, G; Sun, Y; Wang, BY; Wu, YX; Ye, DW; Yu, SY; Zhang, P | 1 |
4 other study(ies) available for iguratimod and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Effects of iguratimod on glucocorticoid-induced disorder of bone metabolism in vitro.
Topics: Alkaline Phosphatase; Animals; Arthritis, Rheumatoid; Bone and Bones; Bone Marrow Cells; Bone Resorption; Calcification, Physiologic; Cell Count; Cell Line; Chromones; Dexamethasone; Down-Regulation; Glucocorticoids; Male; Mice, Inbred C57BL; Osteoblasts; Osteoclasts; Osteogenesis; Sulfonamides; Up-Regulation | 2021 |
Iguratimod prevents ovariectomy‑induced bone loss and suppresses osteoclastogenesis via inhibition of peroxisome proliferator‑activated receptor‑γ.
Topics: Animals; Bone Resorption; Cells, Cultured; Chromones; Disease Models, Animal; Female; Gene Expression Regulation; Genes, fos; Mice; NFATC Transcription Factors; Osteoclasts; Ovariectomy; Postmenopause; PPAR gamma; Protective Agents; RANK Ligand; Sulfonamides; X-Ray Microtomography | 2017 |
Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Resorption; Cell Differentiation; Cell Movement; Chromones; Extracellular Signal-Regulated MAP Kinases; Humans; JNK Mitogen-Activated Protein Kinases; Mice; NF-kappa B; NFATC Transcription Factors; Osteoclasts; Proto-Oncogene Proteins c-fos; RANK Ligand; RAW 264.7 Cells; Signal Transduction; Sulfonamides | 2016 |
Anti-rheumatic drug iguratimod (T-614) alleviates cancer-induced bone destruction via down-regulating interleukin-6 production in a nuclear factor-κB-dependent manner.
Topics: Animals; Apoptosis; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Carcinogenesis; Cell Movement; Cell Proliferation; Chromones; Female; Humans; Interleukin-6; MCF-7 Cells; Neoplasm Invasiveness; Rats; Sulfonamides; Transcription Factor RelA | 2016 |